Alzheimer's Disease Prevalence Rates Rise To More Than Five Million In The United States
Main Category: Alzheimer's / DementiaAlso Included In: Neurology / Neuroscience; Seniors / Aging; Public Health
Article Date: 21 Mar 2007 - 0:00 PST
'Alzheimer's Disease Prevalence Rates Rise To More Than Five Million In The United States'
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
3 (3 votes) |
| Article opinions: | 1 posts |
The Alzheimer's Association today reports that in 2007 there are now more than 5 million people in the United States living with Alzheimer's disease. This number includes 4.9 million people over the age of 65 and between 200,000 and 500,000 people under age 65 with early onset Alzheimer's disease and other dementias. This is a 10 percent increase from the previous prevalence nationwide estimate of 4.5 million.
The greatest risk factor for Alzheimer's is increasing age, and with 78 million baby boomers beginning to turn 60 last year, it is estimated that someone in America develops Alzheimer's every 72 seconds; by mid-century someone will develop Alzheimer's every 33 seconds.
These new estimates, as well as other data concerning the disease and its effects, are issued today as hundreds of advocates from across the country gather in the nation's capitol for the Alzheimer's Association's annual Public Policy Forum. The report titled, 2007 Alzheimer's Disease Facts and Figures, is being released at a hearing today chaired by Senator Barbara Mikulski. Senators Barbara Mikulski and Christopher Bond and Representatives Edward Markey and Christopher Smith have introduced bipartisan legislation to address problems identified in the Association's report. The Association's report details the escalation of Alzheimer's disease which now is the seventh leading cause of death in the country and the fifth leading cause of death for those over age 65. It also offers numerous statistics that convey the burden that Alzheimer's imposes on individuals, families, state and federal governments, businesses, and the nation's health care system. For example:
-- Without a cure or effective treatments to delay the onset or progression of the Alzheimer's, the prevalence could soar to 7.7 million people with the disease by 2030, which is more than the population of 140 of the 236 United Nations countries.
-- By mid-century, the number of people with Alzheimer's is expected to grow to as many as 16 million, more than the current total population of New York City, Los Angeles, Chicago and Houston combined.
-- As the prevalence impact of Alzheimer's grows, so does the cost to the nation. The direct and indirect costs of Alzheimer's and other dementias amount to more than $148 billion annually, which is more than the annual sales of any retailer in the world excluding Wal-Mart.
"Alzheimer's Disease Facts and Figures clearly shows the tremendous impact this disease is having on the nation; and with the projected growth of the disease, the collective impact on individuals, families, Medicare, Medicaid, and businesses will be even greater," says Harry Johns, President and CEO of the Alzheimer's Association. "However there is hope. There are currently nine drugs in Phase III clinical trials for Alzheimer's several of which show great promise to slow or stop the progression of the disease. This, combined with advancements in diagnostic tools, has the potential to change the landscape of Alzheimer's."
According to the latest statistics from the Centers for Disease Control and Prevention, from 2000-2004 death rates have declined for most major diseases -- heart disease (-8 percent), breast cancer (-2.6 percent), prostate cancer (-6.3 percent) and stroke (-10.4 percent), while Alzheimer's disease deaths continue to trend upward, increasing 33 percent during that period.
"We must make the fight against Alzheimer's a national priority before it's too late. The absence of effective disease modifying drugs, coupled with an aging population, makes Alzheimer's the health care crisis of the 21st century," Johns said.
Medicare currently spends nearly three times as much for people with Alzheimer's and other dementias than for the average Medicare beneficiary. Medicare costs are projected to double from $91 billion in 2005 to more than $189 billion by 2015, more than the current gross national product of 86 percent of the world's countries. In 2005, state and federal Medicaid spending for nursing home and home care for people with Alzheimer's and other dementias was estimated at $21 billion; that number is projected to increase to $27 billion by 2015.
The new report also highlights the impact that Alzheimer's has on states with more than 6 in 10 (62%) having double digit growth in prevalence by the end of the decade. In addition, Alaska (+47%), Colorado (+47%), Utah (+45%), Wyoming (+43%), Nevada (+38%), Idaho (+37%), Oregon (+33%), and Washington (+33%) will experience increases ranging from one-third to one-half. The states with the largest numbers of deaths due to Alzheimer's disease in 2003 were (1) California, (2) Florida, (3) Texas, (4) Pennsylvania, and (5) Ohio.
The Alzheimer's Association is the first and largest voluntary health organization dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer's. For more than 25 years, the Association has provided reliable information and care consultation; created services for families; increased funding for dementia research; and influenced public policy changes.
Alzheimer's Association
http://www.alz.org/
Visit our alzheimer's / dementia section for the latest news on this subject.
MLA
26 May. 2012. <http://www.medicalnewstoday.com/releases/65691.php>
APA
http://www.medicalnewstoday.com/releases/65691.php.
Please note: If no author information is provided, the source is cited instead.
Visitor Opinions (latest shown first)
Alzheimer's Disease Estimate Is Excessive
posted by William B. Grant on 21 Mar 2007 at 12:06 pmThis latest report from the Alzheimer’s Association appears to present an inflated estimate of the number of American’s suffering from Alzheimer’s disease (AD). The estimate is based on studies by Hebert et al. [2003, 2004]. In the 2003 study, they assessed AD prevalence rates in a biracial suburb of Chicago, then extrapolated to the entire United States based on factors related to AD prevalence such as level of education. As I pointed out in my letter to the editor [Grant, 2004], that is an incorrect approach when different races are involved since African Americans have a higher prevalence of the APOE epsilon4 allele, which is an important risk factor for AD [Grant, 1998].
Diet is also an important risk factor [Grant, 1997; Luchsinger et al., 2002], and African Americans tend to have diets that pose a greater risk for developing AD than do white Americans. Thus, using their data and recalculating the prevalence for the U.S., I obtained a value of 3.9 million with a range of 3.1 to 4.7 million (95% confidence interval).
However, this value should be compared to other values in the literature. The values by others are usually in the range of 2.3 to 2.5 million (see Table 1), or half of what the Alzheimer’s Association suggests. An additional reason for differences may be that those with vascular dementia are sometimes included in the category of AD. In Western developed countries, approximately 2/3 of dementia is AD, 1/3 is vascular dementia [Jorm, 1991]. However, some of the studies by Evans and Hebert have reported much higher fractions with AD [Evans et al., 1989].
While Alzheimer’s disease is a dreaded disease (my mother died with it), it is important to get the prevalence right before trying to make policies to address it. In addition, since diet plays such an important role, with the rising epidemic of obesity fueling a pending rise in AD prevalence, the top priority should be directed at combating obesity rather than preventing or treating AD with pharmaceutical drugs.
References
Alzheimer’s Association, Alzheimer’s Disease Facts and Figures, 2007. Chicago.
Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998 Sep;88(9):1337-42.
Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990;68(2):267-89.
Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989 Nov 10;262(18):2551-6.
Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60:185-189.
Gatz M, Svedberg P, Pedersen NL, Mortimer JA, Berg S, Johansson B. Education and the risk of Alzheimer's disease: findings from the study of dementia in Swedish twins. J Gerontol B Psychol Sci Soc Sci. 2001 Sep;56(5):P292-300.
Grant WB. Dietary links to Alzheimer's disease. Alz Dis Rev 1997;2:42-55
(http://www.sunarc.org/JAD97.pdf)
Grant WB. The APOE-epsilon4 allele and Alzheimer disease among African Americans, Hispanics, and Whites, JAMA, letter, Nov. 18, 1998;280:162-163.
Grant WB. Year 2000 prevalence of Alzheimer disease in the United States. Arch Neurol. 2004 May;61(5):802-3; author reply 803.
Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, Funkenstein HH, Evans DA. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995 May 3;273(17):1354-9.
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003 Aug;60(8):1119-22.
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. State-specific projections through 2025 of Alzheimer disease prevalence. Neurology. 2004 May 11;62(9):1645.
Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007 Jan 30;68(5):326-37.
Jorm AF. Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci. 1991;240:218-222.
Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002;59:1258-1263.
Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60:940-6.
Table 1. Estimates of Alzheimer’s disease prevalence in the U.S.
Year Conditions Prevalence (millions) Reference
1980 Over 65 years 2.88 Evans, 1990
1989 Over 65 years 3.2 (95% CI, 2.5-3.9) Evans et al., 1989
1997 2.32 (range: 1.09 to 4.58) Brookmeyer et al., 1998
2000 2.3+0.3 Grant, 1997
2003 4.5 Hebert et al., 2003
2004 Recalculation of
Hebert et al., 2003 3.9 (95% CI, 3.1-4.7) Grant, 2004
2007 Over 65 years 2.459 Hirtz et al., 2007
2007 5.1 (4.9 over the age of 65 years) Alzheimer’s Association
CI, confidence interval
Add Your Opinion On This Article
'Alzheimer's Disease Prevalence Rates Rise To More Than Five Million In The United States'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.






